The FDA has handed out two fast track designations aimed at tackling one of oncology's toughest challenges: KRAS-mutant cancers. TRE-515, developed by Trethera Corporation, earned the designation in combination with KRAS inhibitors for patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) who've already been treated with anti-PD-(L)1 therapy and platinum-based chemotherapy. Separately, Kestrel Therapeutics' KST-6051 — a pan-KRAS inhibitor — received fast track status for advanced or metastatic solid tumors harboring any KRAS mutation.

TRE-515 takes a novel metabolic angle: it blocks deoxycytidine kinase (dCK), the key enzyme in the nucleoside salvage pathway that tumors appear to rely on more heavily when under pressure from KRAS inhibitors. KST-6051, meanwhile, targets KRAS in both its active and inactive states — a dual-state approach designed to broaden its reach across KRAS-driven cancers like pancreatic, colorectal, and lung cancer. Both agents are currently in first-in-human Phase 1 trials.

Key Takeaways:

• TRE-515 is a first-in-class dCK inhibitor targeting a metabolic escape route tumors may use under KRAS inhibitor pressure
• KST-6051 inhibits KRAS in both GTP-bound (active) and GDP-bound (inactive) states — a potential differentiator from existing KRAS G12C-specific agents
• Fast track status accelerates FDA interactions and could speed both drugs toward approval if trials succeed

Why it matters: KRAS inhibitors have reshaped lung cancer treatment, but resistance remains a persistent challenge. These two fast track designations reflect growing momentum toward combination and next-generation strategies that could extend the benefit of KRAS-targeted therapy to more patients — and for longer.